Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report

Hai-Ping Liang, Xing-Chun Luo, Ya-Li Zhang, Bei Liu

**Abstract**

**BACKGROUND**

Del(5q) is the most common molecular event in myelodysplastic syndrome (MDS), accounting for 10%-15% of cases. Inv(3) is an adverse cytogenetic abnormality observed in less than 1% of MDS patients. Few studies have reported the coexistence of del(5q) and inv(3) in MDS. Therefore, the pathological mechanism, treatment strategy and prognosis of this subtype need to be elucidated.

**CASE SUMMARY**

A 66-year-old woman was admitted to the hospital due to chest tightness and shortness of breath. Combining clinical assessments with laboratory examinations, the patient was diagnosed with MDS containing both del(5q) and inv(3). Considering the deletion of chromosome 5q, we first treated the patient with lenalidomide. When drug resistance arose, we tried azacitidine, and the patient had a short remission. Finally, the patient refused treatment with haematopoietic stem cell transplantation and died of severe infection four months later.

**CONCLUSION**

MDS patients with del(5) and inv(3) have a poor prognosis. Azacitidine may achieve short-term remission for such patients.

**Key Words:** Myelodysplastic syndrome; Del(5q); Inv(3); Lenalidomide; Azacitidine; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: We report a rare case of myelodysplastic syndrome (MDS) with two chromosomal structural abnormalities, del(5q) and inv(3). The patient evolved from the initial del(5q) to inv(3) combined with del(5q). Considering the deletion of chromosome 5q, we first treated the patient with lenalidomide. When drug resistance arose, we tried azacitidine, and the patient had a short remission. Finally, the patient refused treatment with haematopoietic stem cell transplantation (HSCT), and her condition gradually deteriorated until she was discharged from the hospital. In this rare and contradictory situation, we found that MDS patients with coexisting del(5q) and inv(3) may have a poor prognosis. However, azacitidine may play a role to some extent in MDS with del(5q) and inv(3), and HSCT may be the only way to cure the disease.

Citation: Liang HP, Luo XC, Zhang YL, Liu B. Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report. World J Clin Cases 2022; 10(11): 3601-3608
URL: https://www.wjgnet.com/2307-8960/full/v10/i11/3601.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i11.3601

INTRODUCTION

Myelodysplastic syndrome (MDS) is defined as a typical heterogeneous group of clonal haematopoietic disorders characterized by dysplastic and ineffective haematopoiesis, and approximately 30% of patients progress to acute myeloid leukaemia (AML)[1,2]. The incidence of MDS is associated with age, especially in people 60 years older, and males are more susceptible than females[3]. MDS patients generally have poor outcomes, with a median overall survival of 5 years[2]. According to the International Prognostic Scoring System (IPSS) and revised International Prognostic Scoring System (IPSS-R), cytogenetic abnormalities, especially certain unbalanced abnormalities, have a profound impact on the prognosis of MDS patients[4]. Unbalanced chromosomal abnormalities caused by partial acquisition or deletion of chromosomes are common in MDS[5]. These abnormalities often occur during tumorigenesis and play a crucial role in MDS progression.

Here, we report a case of an MDS patient with clonal progression from del(5q) to inv(3) and del(5q), who was treated with azacitidine after lenalidomide resistance. Furthermore, we will summarize the genetic abnormalities and treatment strategies to add a corresponding contribution to the treatment and prognosis of these patients.

CASE PRESENTATION

Chief complaints
In September 2020, a 66-year-old woman was admitted to our hospital for progressive chest tightness and shortness of breath.

History of present illness
One year prior, the patient had been admitted to the hospital with severe anaemia and thrombocytosis. Physical examination showed that the patient had an anaemic appearance. The results of peripheral blood examination were as follows: red blood cell (RBC) count, 1.0 × 10^{12}/L; platelet (PLT) count, 409 × 10^{9}/L; haemoglobin (HB), 36 g/L; creatinine, 0.55 mg/dL; and lactate dehydrogenase (LDH), 418 U/L. Bone marrow trephine biopsy revealed more than 10% abnormal megakaryocytes (single round nuclei and cytosolic lobulated micronuclei) (Figure 1A). Fluorescence in situ hybridization (FISH) indicated deletion of the EGR1 (5q31) gene (Figure 1B). Furthermore, the karyotype was described as 46, XX, del(5)(q13q31) by G band staining (Figure 1C). Based on clinical manifestations and laboratory tests, the patient was diagnosed with low-risk MDS (low risk, IPSS-R = 2.5). The endothelial activation and stress index (EASIX) was 0.56. EASIX is an independent prognostic factor for lower-risk MDS patents that was calculated by the following formula: LDH (U/L) × creatinine (mg/dL)/PLT (nL)[6]. The patient was advised to be treated with lenalidomide. The dosing schedule was 10 mg/d or 21 d in a 28-d cycle. After three cycles of treatment, peripheral blood examination showed HB 97 g/L and PLT 341 × 10^{9}/L.

History of past illness
The patient was previously healthy. There was no disease history in other systems.

Personal and family history
No contributory personal history or similar family history.
Figure 1 Bone marrow aspiration biopsy, karyotype and fluorescence in situ hybridization assay at first diagnosis. A: Representative image of May Grunwald-Giemsa staining of bone marrow specimen. It is showed that more than 5% blast cell and more than 10% abnormal megakaryocytes, including unicellular megakaryocytes (panel A red arrow) and lymphatic-like small megakaryocytes (yellow arrow). B: EGR(5q31) gene was detected by fluorescence in situ hybridization. Each signal mode was detected as follows: 2G1R 50%, 2G2R 50%. EGR(5q31) probe was labeled with red fluorescence, D5S23 and D5S721(5p15.2) probe was labeled with green fluorescence. C: G-band bone marrow karyotype. Arrows indicate the del(5)(q13q31).

Physical examination
Physical examination showed that the patient had a moderate anaemic appearance. Her vital signs were stable, with no other positive findings.

Laboratory examinations
The results of the peripheral blood examination were as follows: RBC, $2.27 \times 10^{12}$/L; WBC, $1.93 \times 10^{9}$/L; PLT, $114 \times 10^9$/L; and HB, 58 g/L.

Further diagnostic work-up
Bone marrow aspirate smears showed hypercellularity with marked myeloid and erythroid hypoplasia and a blast cell count of 16% (Figure 2A). Another karyotype examination revealed 46, XX, inv(3)(q21q26), and del(5)(q13q31) (Figure 2B). qRT-PCR showed that the EVI1 expression level was 90.63%, which was classified as high expression.

FINAL DIAGNOSIS
According to the IPSS-R, the patient’s diagnosis was revised to high-risk MDS (very high risk, IPSS-R =
Figure 2 Bone marrow aspiration biopsy and karyotype analysis after lenalidomide resistances. A: Bone marrow aspiration smear showing blast cell counted 16% and Hypercellularity with marked myeloid and erythroid hypoplasia. Abnormal megakaryocytes including unicellular megakaryocytes (red arrow) and lymphatic-like small megakaryocytes (yellow arrow) could still be observed. B: karyotype analysis depicting 46, XX, inv(3)(q21q26),del(5)(q13q31) (Red arrow).

TREATMENT

We continued to treat the patient with lenalidomide. In less than one treatment cycle, the patient rapidly developed resistance to the drug. Subsequently, we tried azacitidine as a treatment and administered 75 mg/m²/d intravenously for 7 consecutive days every 28 d. After two courses, haematology showed HB 70 g/L and PLT 56 × 10⁹/L. After the fourth cycle, peripheral blood examination revealed HB 40 g/L and PLT 14 × 10⁹/L. Bone marrow aspirate smears revealed that nucleated cells accounted for 6% of the cell population. A mutation of the ASXL1 gene [NM 015338:c.4232_4233delinsA(p. W1411*) ex 12] with a variant allele frequency of 33.1% was detected. Subsequently, her medical condition gradually deteriorated. In view of the present situation, we recommended HSCT.

OUTCOME AND FOLLOW-UP

The patient was discharged and wilfully refused HSCT. After four months, the patient died of the infection.
DISCUSSION

We report a rare case of MDS with clonal evolution from del(5q) to inv(3) (Figure 3). MDS with del(5q), also known as 5q-syndrome, is a specific type of MDS that has a better prognosis than other subtypes of MDS. The median expected survival time of this syndrome is approximately 58 mo[7]. Deletion of chromosome arm 5q results in the deletion of genes located on this chromosome, including SPARC, EGR1, CTNNA1, APC and NPM1[8]. Based on this, we used LSI EGR1 and D5S23 and a D5S721 dual colour probe to detect del(5q). MDS with inv(3)/t(3) is considered to be a rare event (< 1%); it is an invasive disease with a high risk of developing AML. Furthermore, high expression of EVI1 was observed with chromosome 3 abnormalities in our case. EVI1 is an oncogenic transcriptional regulator that may be involved in the proliferation and maintenance of haematopoietic stem cells, and its abnormally high expression often promotes disease progression[9]. In addition, ASXL1 mutations that frequently occur in MDS were detected in our case and predict an adverse outcome[10]. Therefore, the patient in our report contained “dominant” karyotypes [del(5q)], “inferior” karyotypes [inv(3)] and harmful ASXL1 mutations. However, the prognostic tendency of these patients remains elusive.

Combining bone marrow cytogenetics, the percentage of bone marrow blasts and cytopenia, our patient was classified as low risk according to the IPSS-R at primary diagnosis. In recent years, cardiovascular disease has been considered to be the second most common cause of death among patients with low-risk MDS after haematological complications[11]. Therefore, we used EASIX to assess the patient’s cardiovascular risk, which was 0.56[6]. Because the patient had no previous history of cardiovascular disease and the cardiovascular examination results were negative at admission, we alleviated the patient’s cardiovascular disease concerns. Considering the IPSS-R and EASIX, we preliminarily evaluated the patient had a good prognosis.

Lenalidomide therapy is initially recommended based on age, general conditions, and cytogenetic abnormalities. Since 2005, the Food and Drug Administration of the United States has approved the use of lenalidomide for the treatment of transfusion-dependent low-risk MDS with or without del(5q), and it has been indicated that lenalidomide could reduce transfusion requirements and reverse cytogenetic abnormalities[12]. Lenalidomide is the first and only treatment for cytogenetically defined subsets of MDS disease, especially MDS with del(5q). However, not all patients achieve a long-term response. It was reported that approximately half of patients with del(5q) lost response or progression after 2-3 years of treatment[13]. Indeed, lenalidomide resistance has become a common event in the treatment of MDS.

In our case, lenalidomide treatment initially showed a good response in the patient, but the patient rapidly developed drug resistance after the first remission. Based on the available data, we found that the occurrence of primary resistance to lenalidomide in MDS is mainly related to TP53 mutations. We reviewed the role of TP53 mutations and abnormal p53 pathway activation in myeloid malignant tumours. In del(5q) patients who had a high mutation rate of TP53, the cytogenetic complete remission rate was less than 12% after treatment with lenalidomide[7]. Therefore, it is plausible that there is a high correlation between TP53 mutations and lenalidomide resistance. In addition, lenalidomide upregulates RUNX1 expression in a CRBN- and TP53-dependent manner in del(5q) MDS, and RUNX1 induces megakaryocyte differentiation and apoptosis assisted by GATA2. As a result, lenalidomide resistance occurs when RUNX1 is mutated or downregulated[14]. The secondary or acquired resistance to lenalidomide is associated with the overexpression of PP2A. The overexpression of PP2A leads to the degradation of p53 in red blood cell precursors and the instability of β-catenin, which is more conducive to the evolution of del(5q) clones[15]. However, TP53 and RUNX1 mutations were not detected in our case. The acquired resistance of our patients to lenalidomide may be related to PP2A abnormalities, but further sufficient data is required for further exploration.

After the lenalidomide treatment failed, inv(3) with EVI1 overexpression and ASXL1 mutations occurred in the patient. Based on clinical assessments and laboratory examination, the patient’s diagnosis was revised to high-risk MDS. We then tried to treat the patient with azacitidine, which is a demethylation drug. Demethylation drugs mainly include azacitidine and decitabine, both of which can inhibit DNA methylation by binding to DNA. Interestingly, azacitidine also binds to RNA to inhibit RNA synthesis and protein metabolism[16]. Sallman et al[16] reported a study about the response to azacitidine in del(5q) MDS patients after lenalidomide resistance. Among 18 del(5q) MDS patients treated with azacitidine, the overall response rate was 56%, including a complete response rate of 5.6%, a narrow complete response rate of 11.1%, and a haematological improvement rate of 38.9%. Azacitidine had the same effect in del(5q) and non-del(5q) patients[17]. In the study by Wanquet et al [18], 157 AML/MDS patients with chromosome 3q abnormalities and 27 patients with isolated EVI1 overexpression were treated with azacitidine. The overall response rate was 50%, including a complete remission rate of 29%, and the median overall survival time was 10.6 mo. AML/MDS with 3q abnormalities has a special response to azacitidine, and azacitidine is an appropriate choice before the patient receives allohaematopoietic stem cell transplantation[18]. To date, there have been a few reports on the treatment of MDS with decitabine[3]. Therefore, we believe that azacitidine is a reasonable option for the treatment of MDS after the failure of lenalidomide. Our patient experienced a short-term improvement after 2 courses of azacitidine treatment.
Figure 3 Clonal evolution architecture of the patient. The patient was initially found to have del(5q) with EGR1 gene deletion, so she was diagnosed with MDS (low risk). Following lenalidomide treatment, the patient developed inv(3) with overexpression of EVI1. At that time, the patient’s diagnosis was revised to MDS (very high risk). In addition, the patient also had ASXL1 mutations. The revised international prognostic scoring system (IPSS-R) for myelodysplastic syndrome was calculated according to a previously reported method[24], and the details can be found in Supplementary Table 1. HB: Haemoglobin; PLT: Platelet; IPSS-R: Revised International Prognostic Scoring System.

The condition of our patient worsened again after a short period of time, and we considered HSCT. At present, for both low-risk and high-risk MDS patients, HSCT is still the only curative treatment[19]. Patients under 65 years of age and suitable healthy elderly patients should be strongly recommended for HSCT with a suitable donor with the same human leukocyte antigen[20]. Among high-risk MDS patients undergoing HSCT, 40-50% of patients have achieved a prolonged disease-free survival and have improved over the years[21]. However, the optimal timing of HSCT and the specific chemical regimen before HSCT treatment is still a controversial issue. It is generally believed that an increase in the percentage of bone marrow blasts, especially if it is greater than 10%, is associated with a higher risk of recurrence[22]. In addition, the existence of poor prognostic mutations, especially mutations in TP53, ASXL1 and RUNX1, should be considered for the use of HSCT to reduce the risk of recurrence[23]. However, in our case, when we recommended that the patient undergo HSCT, the patient rejected the recommendation for unknown reasons. Subsequently, the patient chose to leave the hospital voluntarily, and we learned during follow-up that the patient died of serious infection after four months.

CONCLUSION

In summary, we report a rare case of MDS with clonal evolution from del(5q) to inv(3). Although lenalidomide and azacitidine provided temporary remission to the patient, the patient inevitably has a poor prognosis. The complex and heterogeneous pathophysiology of MDS is still the main reason for the limited effectiveness of current treatments; thus, emerging therapeutic strategies are still urgently needed.

FOOTNOTES

Author contributions: Liang HP designed the study and wrote the manuscript; Luo XC collected and analyzed the data; Zhang YL prepared figures; Liu B was in charge of patient treatment and designed the paper; all authors read and approved the final manuscript.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Hai-Ping Liang 0000-0001-7537-278X; Xing-Chun Luo 0000-0002-4576-9011; Ya-Li Zhang 0000-0002-4176-9129; Bei Liu 0000-0003-4331-2138.

S-Editor: Gong ZM
L-Editor: A
P-Editor: Gong ZM

REFERENCES

1. Gorsheim E, Weber UM, Gore S. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? Expert Rev Hematol 2020; 13: 233-239 [PMID: 32067540 DOI: 10.1080/17474086.2020.1730806]
2. Menssen AJ, Walter MJ. Genetics of progression from MDS to secondary leukemia. Blood 2020; 136: 50-60 [PMID: 32430504 DOI: 10.1182/blood.2019000942]
3. Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol 2020; 95: 1399-1420 [PMID: 32744763 DOI: 10.1002/ajh.25950]
4. Hosono N. Genetic abnormalities and pathophysiology of MDS. Int J Clin Oncol 2019; 24: 885-892 [PMID: 31093808 DOI: 10.1007/s10147-019-01462-6]
5. Ogawa S. Genetics of MDS. Blood 2019; 133: 1049-1059 [PMID: 30670442 DOI: 10.1182/blood-2018-10-844621]
6. Merz A, Gerning U, Kobbe G, Kaivers J, Jauch A, Radujkovic A, Hummel M, Benner A, Merz M, Dreger P, Luft T. EASiX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J 2019; 9: 85 [PMID: 31712595 DOI: 10.1038/s41408-019-0247-z]
7. Lee JH, List A, Sallman DA. Molecular pathogenesis in myelodysplastic syndromes with deletion 5q. Eur J Haematol 2019; 102: 203-209 [PMID: 30578738 DOI: 10.1111/ejh.13207]
8. Jädersten M, Karsan A. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring. Haematologica 2011; 96: 177-180 [PMID: 21282717 DOI: 10.3324/haematol.2010.038281]
9. Birdwell C, Fiskus W, Kadia TM, DiNardo CD, Mill CP, Bhalla KN. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J 2021; 11: 64 [PMID: 33753715 DOI: 10.1046/1448-010X-200457-9]
10. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506 [PMID: 21576631 DOI: 10.1200/JCO.2010.33.4938]
11. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Jädersten M, Karsan A. Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. Blood 2020; 135: 2525-2533 [PMID: 32251398 DOI: 10.1182/blood.2019-0497-97]
12. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the management of lower-risk myelodysplastic syndromes with chromosome 3 abnormalities. Genes Chromosomes Cancer 2020; 629-635 [PMID: 30097406 DOI: 10.1002/gcc.23092]
13. Talati C, Sallman DA, List AF. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. Clin Lymphoma Myeloma Leuk 2018; 18: 629-635 [PMID: 30097406 DOI: 10.1016/j.clml.2018.07.293]
14. Martinez-Høyer S, Deng Y, Parker J, Jiang J, Mo A, Docking TR, Gharaei N, Li J, Umlandt P, Fuller M, Jädersten M, Kulasekararaj A, Malcovati L, List AF, Hellström-Lindberg E, Platzbecker U, Karsan A. Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. Nat Cell Biol 2020; 22: 526-533 [PMID: 32251398 DOI: 10.1038/s41556-020-0497-9]
15. Sallman DA, Wei S, List A. P2PA: The Achilles Heal in MDS with 5q Deletion. Front Oncol 2014; 4: 264 [PMID: 25292531 DOI: 10.3389/fonc.2014.00264]
16. Sallman DA, Barnard J, Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancer JE, Kantarjian H, List AF, Konnrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk 2020; 20: e597-e605 [PMID: 32030488 DOI: 10.1016/j.clml.2020.03.005]
17. Iizuka H, Yoshimi A, Yamamoto G, Masuda A, Nannya Y, Ichikawa M, Yatomi Y, Kurokawa M. Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia. Rinshô Ketsueki 2013; 54: 468-472 [PMID: 23278266]
18. Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A, Micel JB, Esterni B, Itzykson R, Thepot S, Recher C, Delaunay J, Deeufs F, Mufli G, Fenaux P, Vey N. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Am J Hematol 2015; 90: 859-863 [PMID: 26113240 DOI: 10.1002/ajh.25950]
19 Garderet L, Ziaigkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Pozrê X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. *Biol Blood Marrow Transplant* 2018; 24: 507-513 [PMID: 29196078 DOI: 10.1016/j.bbmt.2017.11.017]

20 Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U; ESMO Guidelines Committee. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †. *Ann Oncol* 2021; 32: 142-156 [PMID: 33221366 DOI: 10.1016/j.annonc.2020.11.002]

21 de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. *Blood* 2017; 129: 1753-1762 [PMID: 28096091 DOI: 10.1182/blood-2016-06-724500]

22 Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. *Br J Haematol* 2020; 189: 1016-1027 [PMID: 31568568 DOI: 10.1111/bjh.16206]

23 Della Porta MG, Galli A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioielli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubeizzo M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricala S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. *J Clin Oncol* 2016; 34: 3627-3637 [PMID: 27601546 DOI: 10.1200/JCO.2016.67.3616]

24 Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilsticker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood* 2012; 120: 2454-2465 [PMID: 22740453]
